drugset / Trial / NCT03799731
Study for Evaluation of Murlentamab (GM102) Anti-tumoral Activity in Colorectal Cancers
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Phase 2A study, assessing the antitumor activity and the safety profile of GM102, a new compound (monoclonal antibody), administered alone or in combination with chemotherapy in patients with locally advanced or metastatic colorectal cancer. The primary objective of the study is to evaluate the antitumor activity of GM102 single agent and in combination with trifluridine/tipiracil.
Timeline
- Start
- 2018-07-11
- Primary completion
- 2021-01-19
- Completion
- 2021-02-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MURLENTAMAB | Monoclonal antibody | 7 mg/kg | Intravenous |
| Subject | Trifluridine/Tipiracil | Unknown | 35 mg/m2 | Oral |